This is an interim data update with no new efficacy or regulatory decision, limited near-term trading catalyst. The next meaningful binary event is the PiNACLE data update in H2 2026. Current safety and translational data directionally positive but well within expectations for a CAR T therapy; no reason to reposition ahead of pivotal readout.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $13.50entry
- T+1 · 5mo ago +0.37%α −1.39% · $13.55
- T+5 · 5mo ago −5.63%α −6.30% · $12.74
- T+20 · 4mo ago +11.19%α +9.41% · $15.01
- T+60 · 2mo ago +0.22%α −3.04% · $13.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA 2026, including a 97% manufacturing success rate and no Grade ≥3 CRS in 108 patients with R/R LBCL, supporting potential for outpatient administration and durably differentiated responses. However, this is an interim data readout, not a pivotal regulatory event; the key catalyst is the PiNACLE trial data update expected H2 2026, with pivotal data and BLA submission not expected until mid-2027 and H2 2027, respectively.
Key Facts
- 108 patients with R/R LBCL treated with ronde-cel; 97% manufacturing success rate
- No Grade ≥3 CRS across 108 patients; Grade ≥3 ICANS in 8% (prophylaxis) vs 16% (no prophylaxis)
- Translational data: Cytotoxic T cells with Memory Potential (Tcmp) more abundant in durable responders (>12 months) vs progressive disease
- Durable complete responses >12 months observed even in patients with low CD19/CD20 antigen expression
- PiNACLE pivotal trial data update expected H2 2026; pivotal data mid-2027 with BLA submission H2 2027
Financial Impact
Pre-revenue clinical-stage biotech with $320M market cap; no financial data disclosed. Event is a data presentation, not a value-changing catalyst. Stock may see modest movement on perceived safety differentiation, but not transformative until pivotal data.
Risk Factors
- Clinical-stage biotech with no approved products; stock is pre-revenue and highly binary on trial outcomes
- PiNACLE data delay or negative efficacy/safety result would significantly impair valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311241 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers